Vitamin D and prostate cancer: The role of membrane initiated signaling pathways in prostate cancer progression

Journal of Steroid Biochemistry and Molecular Biology

Volumn 121, Issue 1-2, 2010, Pages 413-416

  Karlsson, Sandra ^a   Olausson, Josefin ^a   Lundh, Dan ^a   Sögård, Peter ^a   Mandal, Abul ^a   Holmström, Kjell Ove ^a   Stahel, Anette ^a   Bengtsson, Jenny ^a   Larsson, Dennis ^a  

^a UNIVERSITY OF SKÖVDE   (Sweden)

Author keywords

1,25(OH)2D3; Membrane receptors; NVDR; PDIA3; Prostate cancer; Receptor modeling

Indexed keywords

CALCITRIOL; PROTEIN DISULFIDE ISOMERASE; PROTEIN DISULFIDE ISOMERASE FAMILY A MEMBER 3; PROTEIN DISULFIDE ISOMERASE FAMILY A MEMBER 3 RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG; VITAMIN D; CALCITRIOL RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL MEMBRANE; CELLULAR DISTRIBUTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN EXPRESSION; RNA TRANSLATION; SIGNAL TRANSDUCTION; BINDING SITE; CHEMICAL STRUCTURE; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; PROCEDURES; PROSTATE TUMOR; PROTEIN CONFORMATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THEORETICAL MODEL; TUMOR CELL LINE;

ALLOSTERIC SITE; CELL LINE, TUMOR; CELL MEMBRANE; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MODELS, MOLECULAR; MODELS, THEORETICAL; PROSTATIC NEOPLASMS; PROTEIN CONFORMATION; RECEPTORS, CALCITRIOL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VITAMIN D;

EID: 77954760891     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.03.083     Document Type: Article

References (32)

1. Nelson W.G., De Marzo A.M., Isaacs W.B. Prostate cancer. N. Engl. J. Med. 2003, 439:366-381.
2. Taplin M.E., Ho S.M. Clinical review 134: the endocrinology of prostate cancer. J. Clin. Endocrinol. Metab. 2001, 86:3467-3477.
3. Hellerstedt B.A., Pienta K.J. The current state of hormonal therapy of prostate cancer. CA Cancer J. Clin. 2002, 52:154-179.
4. Feldman B.J., Feldman D. The development of androgen independent prostate cancer. Nat. Rev. Cancer 2001, 1:34-45.
5. 3 metabolism in prostate cancer. J. Steroid Biochem. Mol. Biol. 2004, 92:317-325.
6. Garland C.F., Garland F.C., Gorham E.D., Lipkin M., Newmark H., Mohr S.B., Holick M.F. The role of vitamin D in cancer prevention. Am. J. Public Health 2006, 96(2):252-261.
7. 3-MARRS)-binding protein in rat IEC-6 cells. Steroids 2005, 70(5-7):458-463.
8. 3-MARRS) and phosphate uptake in intestinal cells. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(19):7392-7397.
9. Khanal R.C., Nemere I. Membrane receptors for vitamin D metabolites. Crit. Rev. Eukarot. Gene Expr. 2007, 17(1):31-47.
10. Watson C.S., Lange C.A. Steadying the boat: integrating mechanisms of membrane and nuclear-steroid-receptor signaling. EMBO Rep. 2005, 6(2):116-119.
11. O'Kelly J., Hisatake J., Hisatake Y., Bishop J., Norman A., Koeffler H.P. Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D knockout mice. J. Clin. Invest. 2002, 109:1091-1099.
12. 3 requires the presence of a functional vitamin D nuclear receptor. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:1589-1594.
13. 3 in vivo and in vitro. Mol. Endocrinol. 2004, 18(11):2660-2670.
14. Erben R.G., Soegiarto D.W., Weber K., Zeitz U., Lieberherr M., Gniadecki R., Möller G., Adamski J., Balling R. Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. Mol. Endocrinol. 2002, 16(7):1524-1537.
15. 3 induces translocation of the Vitamin D receptor (VDR) to the plasma membrane in skeletal muscle cells. J. Cell. Biochem. 2002, 86:128-135.
16. Chen T.C., Holick M.F. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol. Metab. 2003, 14(9):423-430.
17. 3-MARRS)-binding protein. J. Steroid Biochem. Mol. Biol. 2004, 89-90(1-5):281-285.
18. 3 binds to catalase. J. Cell. Biochem. 2006, 97:1259-1266.
19. 3 to annexin II: effect of vitamin D metabolites and calcium. J. Cell. Biochem. 2000, 80:259-265.
20. 3 is present in an intestinal caveolae membrane fractio. Biochem. Biophys. Res. Commun. 2002, 298:414-419.
21. Mizwicki M.T., Bula C.M., Bishop J.E., Norman A.W. New insights into vitamin D sterol-VDR proteolysis, allostery, structure-function from the perspective of a conformational ensemble model. J. Steroid Biochem. Mol. Biol. 2007, 103:243-262.
22. 3 signaling: a systems biology approach, critical reviews in eukaryoticsignaling: a systems biology approach. Crit. Rev. Eukaryot. Gene Exp. 2009, 19(3):181-196.
23. Dong G., Wearsch P.A., Peape D.R., Cresswell r.P., Reinisch K.M. Insights into MHC class I peptide loading from the structure of the tapasin-ERP57 thioloxidoreductase heterodimer. J. Immunity 2009, 30:21-32.
24. Š Ali A., Blundell T.L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993, 234:779-815.
25. Kozlov G., Maatanen P., Schrag J.D., Pollock S., Cygler M., Nagar B., Thomas D.Y., Gehring K. Crystal structure of the BB'domains of the protein disulfide isomerase ERP57. Structure 2006, 14:1331-1339.
26. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. Procheck: a program to check the stereochemical quality of protein structures. J. Appl. Cryst. 1993, 26:283-291.
27. 3 in basal lateral membranes of enterocytes from the freshwaterfish Carp. Am. J. Phys. Endocrinol. Metab. 2000, 279:614-621.
28. 3-I: calcium transport, receptor kinetics, and signal transduction in intestine of male chickens. Endocrinology 2003, 144:1726-1735.
29. 3-II: calcium transport, receptor kinetics, and signal transduction in intestine of female chickens. J. Cell. Biochem. 2003, 90:901-913.
30. 3 in osteoblasts. Steroids 2002, 67:235-246.
31. 3 is independent of PDIA3 (1,25-MARRS). Curr. Trends Steroid Res. 2008, 5:17-24.
32. 3 in LNCaP cancer prostate cells. Adv. Exp. Med. Biol. 2008, 617:573-579.